Geraldine Gillespie obtained her DPhil (PhD) in 1997 at Oxford University’s Medical Science Division under the instruction of Prof Paul Moss in Prof John Bell’s laboratory where she studied T cell perturbations in haematological malignancies. She completed a two-year postdoctoral stent thereafter, where by availing of newly developed MHC class I tetramer technology, she re-evaluated CMV-specific CD8+ T cells in healthy individuals. Following a post-doctoral placement in the laboratory of Prof Rowland-Jones, during which time she investigated CD8+ T cell immunity in HLA-B*57+, HIV-infected elite controllers, she obtained an Elizabeth Glaser Pediatrics AIDS Foundation Postdoctoral Fellowship. Subsequently, she was awarded MRC New Investigators Research Award (2006). She was elected Mary Goodger Scholar in 2012 and University Research Lecturer in 2016. Since then, Geraldine has worked closely with Prof Andrew McMichael to study the biology of TCR and KIR receptor interactions with MHC class I. Following the recent discovery that RhCMV-SIV vaccine regimens drive broadly targeting, protective HLA-E restricted CD8+ T cells in rhesus macaques, her work currently focuses on the re-evaluation of the human HLA-E peptide-binding repertoire from a biochemical and structural perspective.